Gyre TherapeuticsGYRE +1.29%39 Days Payable is 14.46 as of Mar. 2026, which is 23% below its 10-year median of 18.78. GuruFocus rates GYRE with a GF Score™ of 39/100 and a GF Value™ of $9.82 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 706 Biotechnology companies, Gyre Therapeutics ranks worse than 92.92% on this metric.
The historical rank and industry rank for Gyre Therapeutics's Days Payable or its related term are showing as below:
GYRE'
s Days Payable Range Over the Past 10 Years
Min: 7.82 Med: 18.78 Max: 22.78
Current: 14.45
During the past 5 years, Gyre Therapeutics's highest Days Payable was 22.78. The lowest was 7.82. And the median was 18.78.
GYRE's Days Payable is ranked worse than 92.92% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs GYRE: 14.45
Gyre Therapeutics's Days Payable
increased
from Mar. 2025 (11.74) to Mar. 2026 (14.46).
It may suggest that Gyre Therapeuticsdelayed paying its suppliers.
Gyre Therapeutics Days Payable Related Terms
Gyre Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Gyre Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gyre Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gyre Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gyre Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Gyre Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Gyre Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gyre Therapeutics (GYRE) has a Days Payable of 14.46 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gyre Therapeutics and its competitors. This is 23% below median its historical median of 18.78. Over the past decade, Gyre Therapeutics' Days Payable has ranged from 7.82 to 22.78. According to the industry distribution chart, Gyre Therapeutics ranks #656 out of 706 companies in the Biotechnology industry, placing it in the top 92.9%.
Is Gyre Therapeutics' Days Payable too high?
Gyre Therapeutics' current Days Payable of 14.46 is 23% below median its 10-year median of 18.78. Over the past 10 years, this metric has ranged from a low of 7.82 to a high of 22.78. The Biotechnology industry median Days Payable is 113.56. Gyre Therapeutics' value of 14.46 is 87.3% below this industry median. Based on the distribution chart, Gyre Therapeutics ranks #656 out of 706 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Gyre Therapeutics has a GF Score™ of 39/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gyre Therapeutics' Days Payable compare to CBIO and RIGL?
According to the Biotechnology industry distribution chart, Gyre Therapeutics ranks #656 out of 706 companies for Days Payable. This places Gyre Therapeutics in the lower half of its industry. The industry median Days Payable is 113.56. Gyre Therapeutics' value of 14.46 is 87.3% below this benchmark. Historically, Gyre Therapeutics' own Days Payable has ranged from 7.82 to 22.78 over the past decade. While the company's 10-year median is 18.78 vs. the industry median of 113.56, Gyre Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gyre Therapeutics's current Days Payable of 14.46 is 87.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Gyre Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gyre Therapeutics's current Days Payable is 14.46, which is 23% below median its own 10-year median of 18.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gyre Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Gyre Therapeutics (GYRE) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.82, compared to a current price of $6.30 — trading 35.8% below its estimated fair value. The current Days Payable is 14.46, which is 23% below median its 10-year median of 18.78 and 87.3% below the Biotechnology industry median of 113.56. Gyre Therapeutics' overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Gyre Therapeutics (GYRE), the current Days Payable is 14.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gyre Therapeutics (GYRE) Overvalued in 2026?
Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued.
The current stock price of $6.30 is trading 35.8% below its estimated GF Value™ of $9.82.
GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.
Key valuation signals for GYRE:
Days Payable: 14.46 (23% below median its 10-year median of 18.78)
GF Value™: $9.82 vs. price of $6.30 (35.8% below fair value)
Industry Position: 87.3% below the Biotechnology median (#656 of 706)
No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score
Get the complete analysis for GYRE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GYRE has been successfully added to your 
